Galectin Therapeutics Logo
Press Releases

Press Releases + New

Date Title and Summary View
Toggle Summary Galectin Therapeutics: Turning Atlanta into America's Next Silicon Valley
Former Silicon Valley Leaders Say Atlanta Emerging as "Silicon Valley for Biotech" and Curing Big Diseases
View HTML
Toggle Summary Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results View HTML
Toggle Summary Galectin Therapeutics Inc. Receives OK from FDA to Proceed with First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis View HTML
Toggle Summary Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with the University of Georgia View HTML
Toggle Summary Galectin Therapeutics Executive Chairman, James Czirr to Appear on "The RedChip Money Report" on FOX Business News View HTML
Toggle Summary Galectin Therapeutics Inc. Announces Submission of an Investigational New Drug (IND) Application for the Treatment of Fatty Liver Disease View HTML
Toggle Summary Galectin Therapeutics Inc. Announces Publication of Galectin Symposium Proceedings by the American Chemical Society View HTML
Toggle Summary New Potential Therapy for Diabetic Kidney Disease: Galectin Therapeutics Announces Anti-Galectin Drug is Effective in Preclinical Studies View HTML
Toggle Summary Galectin Therapeutics Appoints Industry Veteran Rex Horton as Executive Director of Regulatory Affairs and Quality Assurance View HTML
Toggle Summary Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis View HTML